Page 7 - Sarepta News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Want to use the companys experimental drug for myscular dystrophy patients. There are signs the fda will give it fast track priority. The main indexes all advanced for a 5th day. That close for the s p puts it on its longest winning streak for the year. Oil settled at a 7 week high. Gold opens at a more than 2 week low. There are reports ford will name its coo, mark fields to be its new ceo. Current Ceo Alan Mulally has said he will retire before the end of the year. And on the 44th annual earth day, comes the question how earth friendly are you . Eco america did a poll. 71 percent of american...

SPRINGHILL, La. - This week, KTBS 3's Rick Rowe has been featuring Springhill, Louisiana and everything it has to offer. It's all part of this month's KTBS 3 Community Caravan.

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target lifted by Mizuho from $145.00 to $179.00 in a research report sent to investors on Friday morning, Benzinga reports. Mizuho currently has a buy rating on the biotechnology company’s stock. SRPT has been the topic of several other research reports. UBS Group raised their price […]

BioPharma

Viral Vector Market was worth USD 0.60 billion in 2022 and is estimated to grow at a CAGR of 19.7% in the forecasted period. The forecasted revenue hints at a growth of around 2.13 billion USD by 2029.